Cost-effectiveness of 7-day-Holter monitoring alone or in combination with transthoracic echocardiography in patients with cerebral ischemia

Clinical Research in Cardiology

Volumn 102, Issue 12, 2013, Pages 875-884

  Mayer, Felix ^b   Stahrenberg, Raoul ^a   Gröschel, Klaus ^a,c   Mostardt, Sarah ^b   Biermann, Janine ^b   Edelmann, Frank ^a,f   Liman, Jan ^a   Wasem, Jürgen ^b   Goehler, Alexander ^b,d,e   Wachter, Rolf ^a,f   Neumann, Anja ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f German Center for Cardiovascular Research   (Germany)

Author keywords

Atrial fibrillation; Cost effectiveness; Holter monitoring; Markov model; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

AGED; ALGORITHM; ANTICOAGULATION; ARTICLE; BRAIN ISCHEMIA; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; HEART ATRIUM FIBRILLATION; HOLTER MONITORING; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TRANSTHORACIC ECHOCARDIOGRAPHY;

AGED; ALGORITHMS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; HUMANS; MARKOV CHAINS; PATIENT SELECTION; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; STROKE; TIME FACTORS;

EID: 84890553170     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-013-0601-2     Document Type: Article

References (43)

1. Evers SM, Struijs JN, Ament AJ, van Genugten ML, Jager JH, van den Bos GA (2004) International comparison of stroke cost studies. Stroke 35(5):1209-1215. doi: 10.1161/01.STR.0000125860.48180.48
2. Saka O, McGuire A, Wolfe C (2009) Cost of stroke in the United Kingdom. Age Ageing 38(1):27-32. doi: 10.1093/ageing/afn281
3. Kolominsky-Rabas PL, Heuschmann PU, Marschall D, Emmert M, Baltzer N, Neundorfer B, Schoffski O, Krobot KJ (2006) Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen stroke project. Stroke 37(5):1179-1183. doi: 10.1161/01.STR.0000217450.21310.90
4. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY (2012) Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e531S-e575S. doi: 10.1378/chest.11-2304
5. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W, Diener HC (2001) Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 32(11):2559-2566
6. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22(8):983-988
7. Stahrenberg R, Weber-Kruger M, Seegers J, Edelmann F, Lahno R, Haase B, Mende M, Wohlfahrt J, Kermer P, Vollmann D, Hasenfuss G, Groschel K, Wachter R (2010) Enhanced detection of paroxysmal atrial fibrillation by early and prolonged continuous holter monitoring in patients with cerebral ischemia presenting in sinus rhythm. Stroke 41(12):2884-2888. doi: 10.1161/STROKEAHA.110. 591958
8. Crystal E, Connolly SJ (2004) Role of oral anticoagulation in management of atrial fibrillation. Heart 90(7):813-817. doi: 10.1136/hrt.2003.02164290/7/ 813
9. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, Nasco E, Sherman DG, Talbert RL, Marler JR (2003) Lessons from the stroke prevention in atrial fibrillation trials. Ann Intern Med 138(10):831-838. doi: 200305200-00011
10. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146(12):857-867. doi: 146/12/857
11. Stahrenberg R, Edelmann F, Haase B, Lahno R, Seegers J, Weber-Kruger M, Mende M, Wohlfahrt J, Kermer P, Vollmann D, Hasenfuss G, Groschel K, Wachter R (2011) Transthoracic echocardiography to rule out paroxysmal atrial fibrillation as a cause of stroke or transient ischemic attack. Stroke 42:3643-3645
12. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13(4):322-338
13. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Vardas P, Al-Attar N, Alfieri O, Angelini A, Blomstrom-Lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbuchel H, Heldal M, Kristensen SD, Le Heuzey JY, Mavrakis H, Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van Gelder IC, Verheugt FW (2012) 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation*Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. doi: 10.1093/eurheartj/ ehs253
14. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367(9526):1903-1912. doi: 10.1016/S0140-6736(06)68845-4
15. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B (2002) Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 288(19):2441-2448 pii: jcc20007
16. Sullivan PW, Arant TW, Ellis SL, Ulrich H (2006) The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 24(10):1021-1033 pii: 24109
17. O'Brien CL, Gage BF (2005) Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 293(6):699-706. doi: 10.1001/jama.293.6.699
18. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S (2010) Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 9(12):1157-1163. doi: 10.1016/S1474-4422(10)70274-X
19. Ariesen MJ, Claus SP, Rinkel GJ, Algra A (2003) Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 34(8):2060-2065. doi: 10.1161/01.STR.0000080678.09344.8D
20. Hart RG, Boop BS, Anderson DC (1995) Oral anticoagulants and intracranial hemorrhage facts and hypotheses. Stroke 26(8):1471-1477
21. Chambers MG, Koch P, Hutton J (2002) Development of a decision-analytic model of stroke care in the United States and Europe. Value Health 5(2):82-97. doi: 10.1046/j.1524-4733.2002.52011.x
22. Briggs A, Sculpher M (1998) An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13(4):397-409
23. Landesweite Basisfallwerte (2013) Verband der Ersatzkassen e. V. http://wwwvdekcom/vertragspartner/Krankenhaeuser/DRG/landesbasisfallwerte/ 2-lbfw-2005-2011-epdf. Accessed 10 June 2013
24. Begleitforschung gem § 17b Abs. 8 KHG (2013) InEK - Institut für das Entgeltsystem im Krankenhaus. http://www.g-drg.de/cms/ Begleitforschung-gem.-17b-Abs.-8-KHG. Accessed 13 June 2013
25. Schilling M, Kiefer R, Busse O (2013) Kodierleitfaden Schlaganfall der DSG und DGN 2011. http://www.idrg.de/uploads/media/Kodierleitfaden-DSG-DGN-2011- Schlaganfall.pdf. Accessed 14 June 2013
26. Webgrouper DRG Research Group Medizinisches Management (2013) website: Universitätsklinikum Münster. http://drg.uni-muenster.de/index.php. Accessed 14 June, 2013
27. Brüggenjürgen B, Rupprecht H, Willich S, Spannagl M, Ehlken B, Smala A, Berger K, Diener H (2005) Cost of atherothrombotic diseases-myocardial infarction, ischaemic stroke and peripheral arterial occlusive disease-in Germany. J Public Health 13:216-224
28. Hein L (2010) Antikoagulantien und Thrombozytenaggregationshemmer. In: Arzneiverordnungs-Report 2010: Aktuelle Daten. Kosten, Trends Und Kommentare. Springer, Heidelberg, pp 409-424
29. Ärztegehälter im Vergleich (2013) website: Vereinigung der kommunalen Arbeitgeberverbände. http://wwwvkade/media/exe/59/ 5e98017fbd2136876f289d29949ebc35/110908-vergleich-aerzeteentgeltepdf. Accessed 10 June 2013
30. Tauch J (2003) Personalbedarfsermittlung im Krankenhaus- Personalbedarfsermittlung im DRG-Zeitalter, 5th edn., edn. Gütersloher Organisationsberatung, Gütersloh
31. Gage BF, Cardinalli AB, Albers GW, Owens DK (1995) Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 274(23):1839-1845
32. Tengs TO, Lin TH (2003) A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 21(3):191-200 pii:210304
33. Haacke C, Althaus A, Spottke A, Siebert U, Back T, Dodel R (2006) Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke 37(1):193-198. doi: 10.1161/01.STR.0000196990. 69412.fb
34. Christensen MC, Mayer S, Ferran JM (2009) Quality of life after intracerebral hemorrhage: results of the factor seven for acute hemorrhagic stroke (FAST) trial. Stroke 40(5):1677-1682. doi: 10.1161/STROKEAHA.108.538967
35. Liao J, Khalid Z, Scallan C, Morillo C, O'Donnell M (2007) Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke 38(11):2935-2940. doi: 10.1161/STROKEAHA.106.478685
36. Barthelemy JC, Feasson-Gerard S, Garnier P, Gaspoz JM, Da Costa A, Michel D, Roche F (2003) Automatic cardiac event recorders reveal paroxysmal atrial fibrillation after unexplained strokes or transient ischemic attacks. Ann Noninvasive Electrocardiol 8(3):194-199 pii:08305
37. Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R (2004) Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 35(7):1647-1651. doi: 10.1161/01.STR.0000131269.69502.d901.STR.0000131269.69502. d9
38. Kamel H, Hegde M, Johnson DR, Gage BF, Johnston SC (2010) Cost-effectiveness of outpatient cardiac monitoring to detect atrial fibrillation after ischemic stroke. Stroke 41(7):1514-1520. doi: 10.1161/STROKEAHA.110.582437
39. Gold JS, Russel LB, Weinstein MC (1996) Cost-effectiveness in Health and Medicine. Oxford University Press, New York
40. Wachter R, Stahrenberg R, Groschel K (2011) Letter by Wachter, et al. regarding article "Cost-effectiveness of outpatient cardiac monitoring to detect atrial fibrillation after ischemic stroke". Stroke 42(3):e36-e37. doi: 10.1161/STROKEAHA.110.604173 Author reply
41. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139-1151. doi: 10.1056/NEJMoa0905561
42. Bruggenjurgen B, Rossnagel K, Roll S, Andersson FL, Selim D, Muller-Nordhorn J, Nolte CH, Jungehulsing GJ, Villringer A, Willich SN (2007) The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. Value Health 10(2):137-143. doi: 10.1111/j.1524-4733.2006.00160.x
43. Weimar C, Weber C, Wagner M, Busse O, Haberl RL, Lauterbach KW, Diener HC (2003) Management patterns and health care use after intracerebral hemorrhage. a cost-of-illness study from a societal perspective in Germany. Cerebrovasc Dis 15(1-2):29-36 pii:ced15029